Kidney Function Tests Market
Description
Size, Share & Trends Analysis Report By Product (Clearance Tests, Urine Tests, Blood Tests, Dilution And Concentration Tests), By End Use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2026 - 2033
Kidney Function Tests Market Summary
The global kidney function tests market size was valued at USD 1.12 billion in 2025 and is projected to reach USD 1.77 billion by 2033, growing at a CAGR of 5.87% from 2026 to 2033. Several factors are anticipated to drive market growth, including increased investments by industry players, growing research and development efforts, a high prevalence of renal diseases, government initiatives, and advancements in technology.
For instance, in February 2024, Simple HealthKit launched a new renal evaluation test for diabetes. The test is available for clinics and at home settings. Such developments are likely to propel the growth of kidney function tests industry.
During the COVID-19 pandemic, the incidence of renal injury increased significantly. Research highlighted that the individuals with pre-existing renal conditions faced a higher risk of severe complications and poorer outcomes upon contracting COVID-19. Ongoing studies on the long-term effects of COVID-19 have also revealed its potential lasting impact on renal health. However, the pandemic disrupted healthcare services for renal disease patients, as lockdowns and social distancing mandates led to temporary closures of non-emergency medical services. This resulted in delays in diagnosing renal diseases due to the suspension of routine visits and diagnostic tests during peak pandemic phases.
The rising prevalence of acute kidney injury (AKI) and its progression to CKD is expected to propel the kidney function tests industry in the forecast period. CKD refers to persistent structural and functional abnormalities in the kidneys lasting at least three months. Conditions such as lifestyle-related diseases and kidney injuries are major contributors to CKD, which remains a global health burden and a leading cause of morbidity and mortality worldwide. According to the World Health Organization (WHO), renal disease has risen to become one of the top 10 leading causes of death globally over the past decade. Additionally, the National Kidney Foundation reports that approximately 37 million people in the U.S., or over one in seven adults, are affected by some form of renal disease.
Global Kidney Function Tests Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global kidney function tests on the basis of product, end use, and region.
Kidney Function Tests Market Summary
The global kidney function tests market size was valued at USD 1.12 billion in 2025 and is projected to reach USD 1.77 billion by 2033, growing at a CAGR of 5.87% from 2026 to 2033. Several factors are anticipated to drive market growth, including increased investments by industry players, growing research and development efforts, a high prevalence of renal diseases, government initiatives, and advancements in technology.
For instance, in February 2024, Simple HealthKit launched a new renal evaluation test for diabetes. The test is available for clinics and at home settings. Such developments are likely to propel the growth of kidney function tests industry.
During the COVID-19 pandemic, the incidence of renal injury increased significantly. Research highlighted that the individuals with pre-existing renal conditions faced a higher risk of severe complications and poorer outcomes upon contracting COVID-19. Ongoing studies on the long-term effects of COVID-19 have also revealed its potential lasting impact on renal health. However, the pandemic disrupted healthcare services for renal disease patients, as lockdowns and social distancing mandates led to temporary closures of non-emergency medical services. This resulted in delays in diagnosing renal diseases due to the suspension of routine visits and diagnostic tests during peak pandemic phases.
The rising prevalence of acute kidney injury (AKI) and its progression to CKD is expected to propel the kidney function tests industry in the forecast period. CKD refers to persistent structural and functional abnormalities in the kidneys lasting at least three months. Conditions such as lifestyle-related diseases and kidney injuries are major contributors to CKD, which remains a global health burden and a leading cause of morbidity and mortality worldwide. According to the World Health Organization (WHO), renal disease has risen to become one of the top 10 leading causes of death globally over the past decade. Additionally, the National Kidney Foundation reports that approximately 37 million people in the U.S., or over one in seven adults, are affected by some form of renal disease.
Global Kidney Function Tests Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global kidney function tests on the basis of product, end use, and region.
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Clearance Tests
- Urine Tests
- Blood Tests
- Dilution And Concentration Tests
- Other Tests
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic Laboratories
- Research Laboratories and Institutes
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. End use
- 1.2.3. Application
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. End use outlook
- 2.2.3. Application outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Kidney Function Tests Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Introduction Of Innovative Kidney Function Tests
- 3.2.1.2. Increasing Investments In R&D
- 3.2.1.3. Increasing Prevalence of Acute Kidney Injury And Associated Chronic Kidney Disease
- 3.2.2. Market restraint analysis
- 3.2.2.1. Low Awareness Regarding Kidney Diseases
- 3.3. Kidney Function Tests Market Analysis Tools
- 3.3.1. Industry Analysis – Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Kidney Function Tests Market: Product Estimates & Trend Analysis
- 4.1. Product Market Share, 2025 & 2033
- 4.2. Segment Dashboard
- 4.3. Global Kidney Function Tests Market by Product Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 4.4.1. Clearance Tests
- 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
- 4.4.2. Blood Tests
- 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.4.3. Urine Tests
- 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.4.4. Dilution & Concentration Tests
- 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.4.5. Other Tests
- 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 5. Kidney Function Tests Market: End Use Estimates & Trend Analysis
- 5.1. End Use Market Share, 2025 & 2033
- 5.2. Segment Dashboard
- 5.3. Global Kidney Function Tests Market by End Use Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 5.4.1. Hospitals
- 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
- 5.4.2. Diagnostic Laboratories
- 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.3. Research Laboratories And Institutes
- 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.4. Others
- 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 6. Kidney Function Tests Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Share Analysis, 2025 & 2033
- 6.2. Regional Market Dashboard
- 6.3. Global Regional Market Snapshot
- 6.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 6.5. North America
- 6.5.1. U.S.
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.2. Canada
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.3. Mexico
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework/ reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million
- 6.6. Europe
- 6.6.1. UK
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.2. Germany
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.3. France
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Regulatory framework/ reimbursement structure
- 6.6.3.3. Competitive scenario
- 6.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.4. Italy
- 6.6.4.1. Key country dynamics
- 6.6.4.2. Regulatory framework/ reimbursement structure
- 6.6.4.3. Competitive scenario
- 6.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.5. Spain
- 6.6.5.1. Key country dynamics
- 6.6.5.2. Regulatory framework/ reimbursement structure
- 6.6.5.3. Competitive scenario
- 6.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.6. Norway
- 6.6.6.1. Key country dynamics
- 6.6.6.2. Regulatory framework/ reimbursement structure
- 6.6.6.3. Competitive scenario
- 6.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.7. Sweden
- 6.6.7.1. Key country dynamics
- 6.6.7.2. Regulatory framework/ reimbursement structure
- 6.6.7.3. Competitive scenario
- 6.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.8. Denmark
- 6.6.8.1. Key country dynamics
- 6.6.8.2. Regulatory framework/ reimbursement structure
- 6.6.8.3. Competitive scenario
- 6.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7. Asia Pacific
- 6.7.1. Japan
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.2. China
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.3. India
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework/ reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.4. Australia
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework/ reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.5. South Korea
- 6.7.5.1. Key country dynamics
- 6.7.5.2. Regulatory framework/ reimbursement structure
- 6.7.5.3. Competitive scenario
- 6.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.6. Thailand
- 6.7.6.1. Key country dynamics
- 6.7.6.2. Regulatory framework/ reimbursement structure
- 6.7.6.3. Competitive scenario
- 6.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 6.8. Latin America
- 6.8.1. Brazil
- 6.8.1.1. Key country dynamics
- 6.8.1.2. Regulatory framework/ reimbursement structure
- 6.8.1.3. Competitive scenario
- 6.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 6.8.2. Argentina
- 6.8.2.1. Key country dynamics
- 6.8.2.2. Regulatory framework/ reimbursement structure
- 6.8.2.3. Competitive scenario
- 6.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9. MEA
- 6.9.1. South Africa
- 6.9.1.1. Key country dynamics
- 6.9.1.2. Regulatory framework/ reimbursement structure
- 6.9.1.3. Competitive scenario
- 6.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9.2. Saudi Arabia
- 6.9.2.1. Key country dynamics
- 6.9.2.2. Regulatory framework/ reimbursement structure
- 6.9.2.3. Competitive scenario
- 6.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9.3. UAE
- 6.9.3.1. Key country dynamics
- 6.9.3.2. Regulatory framework/ reimbursement structure
- 6.9.3.3. Competitive scenario
- 6.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 6.9.4. Kuwait
- 6.9.4.1. Key country dynamics
- 6.9.4.2. Regulatory framework/ reimbursement structure
- 6.9.4.3. Competitive scenario
- 6.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. Key company market share analysis, 2025
- 7.3.2. Abbott
- 7.3.2.1. Company overview
- 7.3.2.2. Financial performance
- 7.3.2.3. Product benchmarking
- 7.3.2.4. Strategic initiatives
- 7.3.3. Danaher
- 7.3.3.1. Company overview
- 7.3.3.2. Financial performance
- 7.3.3.3. Product benchmarking
- 7.3.3.4. Strategic initiatives
- 7.3.4. F. Hoffmann-La Roche Ltd
- 7.3.4.1. Company overview
- 7.3.4.2. Financial performance
- 7.3.4.3. Product benchmarking
- 7.3.4.4. Strategic initiatives
- 7.3.5. Sysmex Corporation
- 7.3.5.1. Company overview
- 7.3.5.2. Financial performance
- 7.3.5.3. Product benchmarking
- 7.3.5.4. Strategic initiatives
- 7.3.6. Siemens Healthineers
- 7.3.6.1. Company overview
- 7.3.6.2. Financial performance
- 7.3.6.3. Product benchmarking
- 7.3.6.4. Strategic initiatives
- 7.3.7. Randox Laboratories Ltd
- 7.3.7.1. Company overview
- 7.3.7.2. Financial performance
- 7.3.7.3. Product benchmarking
- 7.3.7.4. Strategic initiatives
- 7.3.8. Quest Diagnostics
- 7.3.8.1. Company overview
- 7.3.8.2. Financial performance
- 7.3.8.3. Product benchmarking
- 7.3.8.4. Strategic initiatives
- 7.3.9. Acon Laboratories, Inc
- 7.3.9.1. Company overview
- 7.3.9.2. Financial performance
- 7.3.9.3. Product benchmarking
- 7.3.9.4. Strategic initiatives
- 7.3.10. Nova Biomedical Corporation
- 7.3.10.1. Company overview
- 7.3.10.2. Financial performance
- 7.3.10.3. Product benchmarking
- 7.3.10.4. Strategic initiatives
- 7.3.11. Laboratory Corporation Of America Holdings
- 7.3.11.1. Company overview
- 7.3.11.2. Financial performance
- 7.3.11.3. Product benchmarking
- 7.3.11.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

